CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sharp Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sharp Therapeutics Corp
2403 Sidney St, Suite 264
Phone: (412) 206-5303p:412 206-5303 PITTSBURGH, PA  15203  United States Ticker: SHRXSHRX
Business Summary
Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases. Its discovery platform combines high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. Its technology includes CoreX assay technology, AlloChem compound libraries, and mine data system and machine learning layer. Its advanced programs include a small molecule that prevents the degradation of the neuroprotective protein progranulin, thus increasing progranulin levels preventing neurodegeneration, and a small molecule that restores activity of mutated GCase protein (mutation and loss of activity of GCase is the genetic cause of Gaucher’s disease).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Company Secretary, Director LorneSugarman 54 1/1/2023 10/4/2021
Chief Financial Officer EdwardJonasson 55 9/28/2022 9/28/2022
Independent Director JasonBaibokas 47 5/2/2023 5/2/2023
Independent Director MarkDickinson 50 11/30/2022 11/30/2022
Independent Director Jason D.Meretsky 55 10/4/2021 10/4/2021

Subsidiaries
Business Name Address City State/Province Country
Sharp Edge Labs, Inc. 2403 Sidney St. Pittsburgh PA United States

Business Names
Business Name
EVP.P
Sharp Edge Labs, Inc.
SHRX

General Information
Outstanding Shares: 8,545,200 (As of 9/30/2024)
Stock Exchange: CVE


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, June 6, 2025